N (%) or M ± SD | ||
Characteristics | Male (N = 6) | Female (N = 6) |
Age | 66.2 ± 7.1 | 65.5 ± 5.7 |
Elderly (≥65 years) | 4 (66.7) 69.5 ± 5.9 | 5 (83.3) 67.2 ± 4.4 |
Not Elderly (<65 years) | 2 (33.3) 59.5 ± 3.5 | 1 (16.7) 57.0 ± 0.0 |
Employed | ||
Yes | 2 (33.3) | 1 (16.7) |
No | 4 (66.7) | 5 (83.3) |
Married | ||
Yes | 4 (66.7) | 5 (83.3) |
No | 2 (33.3) | 1 (16.7) |
Smoking history | ||
Yes | 6 (100.0) | 2 (33.3) |
No | 0 (0.0) | 4 (66.7) |
Diagnosis Stage | ||
Postoperative Recurrence | 1 (16.7) | 1 (16.7) |
III | 1 (16.7) | 0 (0.0) |
IV | 4 (66.7) | 5 (83.3) |
Surgery history | ||
Yes | 2 (33.3) | 1 (16.7) |
No | 4 (66.7) | 5 (83.3) |
Chemotherapy history | ||
Yes | 2 (33.3) | 2 (33.3) |
No | 4 (66.7) | 4 (66.7) |
ECOG Performance Status | ||
0 (Baseline/4 weeks follow-up) | 3 (50.0)/0 (0.0) | 3 (50.0)/2 (33.3) |
1 (Baseline/4 weeks follow-up) | 2 (33.3)/4 (66.7) | 3 (50.0)/2 (33.3) |
≥2 (Baseline/4 weeks follow-up) | 1 (16.7)/2 (33.3) | 0 (0.0)/2 (33.3) |
EGFR Inhibitors | ||
Gefitinib | 1 (16.7) | 0 (0.0) |
Erlotinib | 0 (0.0) | 1 (16.7) |
Afatinib | 5 (83.3) | 2 (33.3) |
Osimertinib | 0 (0.0) | 3 (50.0) |